“Metabolic reprogramming” in ovarian cancer cells resistant to cisplatin
M Montopoli, M Bellanda, F Lonardoni… - Current Cancer Drug …, 2011 - ingentaconnect.com
M Montopoli, M Bellanda, F Lonardoni, E Ragazzi, P Dorigo, G Froldi, S Mammi…
Current Cancer Drug Targets, 2011•ingentaconnect.comThe way cancer cells escape cisplatin-induced apoptosis has not been completely
elucidated yet. We questioned the relevance of “metabolic reprogramming” in cisplatin-
resistance by studying mitochondrial function and metabolism in human ovarian carcinoma
cell lines, cisplatin-sensitive (2008) and-resistant (C13). C13 cells, in comparison to 2008
cells, showed lower apoptotic response to cisplatin exposure, lower basal oxygen
consumption (4.2±0.2 vs 6.5±0.7 fmol/cell/min, p
elucidated yet. We questioned the relevance of “metabolic reprogramming” in cisplatin-
resistance by studying mitochondrial function and metabolism in human ovarian carcinoma
cell lines, cisplatin-sensitive (2008) and-resistant (C13). C13 cells, in comparison to 2008
cells, showed lower apoptotic response to cisplatin exposure, lower basal oxygen
consumption (4.2±0.2 vs 6.5±0.7 fmol/cell/min, p
The way cancer cells escape cisplatin-induced apoptosis has not been completely elucidated yet. We questioned the relevance of “metabolic reprogramming” in cisplatin-resistance by studying mitochondrial function and metabolism in human ovarian carcinoma cell lines, cisplatin-sensitive (2008) and -resistant (C13). C13 cells, in comparison to 2008 cells, showed lower apoptotic response to cisplatin exposure, lower basal oxygen consumption (4.2±0.2 vs 6.5±0.7 fmol/cell/min, p
ingentaconnect.com